Watch: Big Week For Drug Pricing Debate Featured On C-SPAN
KHN correspondent Emmarie Huetteman appeared on the C-SPAN program “Washington Journal,” where she fielded viewers’ calls about high drug prices and industry criticism.
Drug Costs
401 - 420 of 702 Results
-
-
Americans Ready To Crack Down On Drug Prices That Force Some To Skip Doses
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
By Jay Hancock -
Podcast: KHN’s ‘What The Health?’ ‘Medicare-For-All’ Debate: Who’s Going To Pay
Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Jennifer Haberkorn of the Los Angeles Times join KHN’s Julie Rovner to discuss the new “Medicare-for-all” bill introduced by House Democrats, the grilling of pharmaceutical company CEOs by a Senate committee and new Trump administration rules that take aim at Planned Parenthood. Plus, Rovner interviews KHN’s Julie Appleby about the latest “Bill of the Month” installment.
-
Pharma Execs Dig In For A Fight Against Outraged Senators
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
By Emmarie Huetteman and Jay Hancock -
Congress Squares Off With Pharma CEOs In Showdown Over High Drug Prices
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
By Emmarie Huetteman and Jay Hancock -
In Florida, Drug Importation From Canada Finds New Champions, Old Snags
The state’s governor said the plan has the full support of the White House. But the Trump administration was noncommittal about whether allowing states to buy and import cheaper drugs from up north could be the answer to the nation’s drug-pricing problem.
By Shefali Luthra and Phil Galewitz -
Video: High Drama No Stranger At Congressional Health Care Hearings
Most hearings before the U.S. House and Senate are routine affairs. But a few tense moments featuring everyone from Hillary Clinton to tobacco CEOs drew the attention of millions of Americans.
By Julie Rovner and Mary Agnes Carey -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Talk About Déjà Vu: Senators Set To Re-Enact Drug Price Hearing Of 60 Years Ago
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
By Jay Hancock -
Today’s Concerns About Drug Prices Echo The Past
Confrontational hearings 60 years ago sparked remarkably similar quotes about drug prices and health care policy.
-
Podcast: KHN’s ‘What The Health?’ How Safe Are Your Supplements?
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
-
The High Cost Of Sex: Insurers Often Don’t Pay For Drugs To Treat Problems
Medicare and many private insurers view prescribing drugs to improve sexual function as a lifestyle issue that’s not medically necessary to pay for.
-
Can California Beat The Federal Government In Lowering Drug Prices?
Unwilling to wait for federal action, California Gov. Gavin Newsom says he has a plan that could extract discounts from drugmakers and save the state money — one he hopes other states can join.
-
Americans Cross Border Into Mexico To Buy Insulin At A Fraction Of U.S. Cost
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Podcast: KHN’s ‘What The Health?’ A ‘Healthy’ State Of The Union
Health was a featured player in President Donald Trump’s 2019 State of the Union address. The president set goals to bring down prescription drug prices, end the HIV epidemic in the U.S. and cure childhood cancer, among other things. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Alice Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN senior correspondent Phil Galewitz about the current “Bill of the Month” feature.
-
Trump Administration Salutes Parade Of Generic Drug Approvals, But Hundreds Aren’t For Sale
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
By Sydney Lupkin and Jay Hancock -
Trump Highlights Health Agenda With Vow To Lower ‘Unfair’ Drug Prices
The president laid out a series of goals, including lowering prescription prices, pursuing an end to the HIV epidemic and boosting funding for childhood cancers.
By Julie Rovner -
Winners And Losers Under Bold Trump Plan To Slash Drug Rebate Deals
The White House and HHS want to eliminate a “shadowy system of kickbacks” in the drug industry pipeline.
By Jay Hancock -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.